With so many payment and care organization approaches, ACOs are focused on obtaining value for their money spent. Today when an oncologist selects a therapy option for their patient, they rely on clinical trials that study large groups of patients with the same cancer. These trials are considered a success if 20-40% of patients respond to the therapy.

Wouldn't treatment be far better if the oncologist could use biomarkers that improved the response rates to 70-80% instead? Oncologists and patients would be ecstatic and payers would be getting far more value for the money they spend on cancer therapies.

In the era of accelerating scientific and medical advancements in personalized oncology, it is increasingly important to explore the impact of adopting medical advances and innovative groundbreaking concepts will share their perspectives.